Tripping on the Couch: Systematic lit review of psychedelic-assisted psychotherapy. Heather Harden скачать в хорошем качестве

Tripping on the Couch: Systematic lit review of psychedelic-assisted psychotherapy. Heather Harden

Therapeutic treatments with psychedelic drugs have a tumultuous history of discovery, prohibition, and resurgence. Recent research on their therapeutic benefits has demonstrated promising potential for treating a wide range of intractable psychiatric diagnoses. Given the treatments’ complex integration of pharmacology and psychotherapy, and the ongoing attempts to approve the compounds for medical use, psychedelic-assisted therapies and their clinical trials warrant in-depth examination. Representing a perspective from within psychotherapy, I conducted a systematic literature review that investigates how psychedelic therapy trials incorporate a psychotherapeutic element in their methodologies. It also explores how different psychotherapy interventions might affect clinical trial outcomes. The research findings shed light on the biases that appear to exist within the recent clinical trials on psychedelic-assisted therapies, which have important implications for their future investigation and development. Researchers and practitioners alike will gain insight into the nature of psychedelics and their fascinating combination with psychotherapy, which is quickly gaining momentum as an innovative new treatment in mental health. Selected studies included in the review: Bogenschutz et al., 2015 Carhart-Harris et al., 2018 Carhart-Harris et al., 2016 Danforth et al., 2018 Garcia-Romeu, Griffiths, & Johnson, 2015 Gasser et al., 2014 Griffiths et al., 2016 Grob et al., 2011 Johnson et al., 2014 Krupitsky et al., 2002 Mithoefer et al., 2018 Mithoefer et al., 2010 Moreno et al., 2006 Oehen et al., 2013 Ot’alora et al., 2018 Ross et al., 2016 References: Belouin, S. J., & Henningfield, J. E. (2018). Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology, 142, 7-19. Bonson, K. (2017). Regulation of human research with LSD in the United States (1949- 1987). Psychopharmacology, 235, 591-604. Carhart-Harris, R. L., & Goodwin, G. M. (2017). The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology, 42, 2105–2113. Courtwright, D. T. (2004). The Controlled Substances Act: how a “big tent” reform became a punitive drug law. Drug and Alcohol Dependence, 76(1), 9-15. Engel, G. L. (1977). The Need for a New Medical Model: A Challenge for Miomedicine. Science, 196(4286), 129–136. Grinspoon, L., & Bakalar, J. B. (1979). Psychedelic Drugs Reconsidered. New York: Basic Books. Hartogsohn, I. (2016). Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology, 30(12), 1259–1267. Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human Hallucinogen Research: Guidelines for Safety. Journal of Psychopharmacology, 22(6), 603–620. https://doi.org/10.1177/0269881108093587 Leuner, H. C. (1967). Present state of psycholytic therapy and its possibilities. In H. A. Abramson (Ed.) The Use of LSD in Psychotherapy and Alcoholism (pp. 101-116). Indianapolis: The Bobbs-Merrill. Mithoefer, M. C., & Emerson, A. (2017). A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder (8th ed.). Santa Cruz, CA: MAPS. Muttoni, S., Ardissino, M., & John, C. (2019). Classical psychedelics for the treatment of depression and anxiety: A systematic review. Journal of Affective Disorders, 258, 11–24. Rigg, K. K., Cook, H. H., & Murphy, J. W. (2014). Expanding the scope and relevance of health interventions: Moving beyond clinical trials and behavior change models. International Journal of Qualitative Studies on Health and Well-being, 9(1), 24743. Rucker, J. J., Jelen, L. A., Flynn, S., Frowde, K. D., & Young, A. H. (2016). Psychedelics in the treatment of unipolar mood disorders: a systematic review. Journal of Psychopharmacology, 30(12), 1220–1229. Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016). Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology Review, 6(3), 193–213. Schenberg, E. E. (2018). Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. Frontiers in Pharmacology, 9(733), 1–11. Schunemann, H. J., Fretheim, A., & Oxman, A. D. (2006). Improving the use of research evidence in guideline development: Grading evidence and recommendations. Health Research Policy and Systems, 4, 21. WHO. (2013). Mental Health Action Plan 2013-2020. Geneva, Switzerland: WHO. Retrieved on 19 January 2020 online. WHO. (2017). Depression and Other Common Mental Disorders: Global Health Estimates. Geneva, Switzerland: WHO. Retrieved on 19 January 2020 online. Wegener, G., & Rujescu, D. (2013). The current development of CNS drug research. International Journal of Neuropsychopharmacology, 16, 1687-1693.